{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:19:50Z","timestamp":1794345590938,"version":"4.9.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000848","name":"University of Edinburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.critrevonc.2025.104655","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T20:05:54Z","timestamp":1738958754000},"page":"104655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["HER2-targeted therapies: Unraveling their role in biliary tract cancers"],"prefix":"10.1016","volume":"208","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6725-2228","authenticated-orcid":false,"given":"Charalampos","family":"Theocharopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis A.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Mungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elissaios","family":"Kontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104655_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib3","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andre","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104655_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.860339","article-title":"Lapatinib suppresses HER2-overexpressed cholangiocarcinoma and overcomes ABCB1- mediated gemcitabine chemoresistance","volume":"12","author":"Bai","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1097-2765(03)00350-2","article-title":"An open-and-shut case? Recent insights into the activation of EGF\/ErbB receptors","volume":"12","author":"Burgess","year":"2003","journal-title":"Mol. Cell"},{"issue":"10075","key":"10.1016\/j.critrevonc.2025.104655_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104655_bib7","article-title":"Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2\/3 amplification (amp), overexpression (oe), or mutation (mut): results from the targeted agent and profiling utilization registry (TAPUR) study","volume":"41","author":"Cannon","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104655_bib8","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104655_bib9","article-title":"HER2 positivity is affected by the papillary structure and has a bidirectional prognostic value for gallbladder carcinoma","volume":"12","author":"Chen","year":"2021","journal-title":"Front Genet"},{"key":"10.1016\/j.critrevonc.2025.104655_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-018-0630-4","article-title":"Targeting ERBB2 mutations in solid tumors: biological and clinical implications","volume":"11","author":"Cousin","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104655_bib12","article-title":"Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India","volume":"38","author":"Das","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104655_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2025.104655_bib14","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.2147\/DDDT.S250061","article-title":"In vitro and in vivo anti-tumor effects of Pan-HER inhibitor varlitinib on cholangiocarcinoma cell lines","volume":"14","author":"Dokduang","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1535-7163.MCT-09-0140","article-title":"Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer","volume":"8","author":"Dokmanovic","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104655_bib16","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1074\/jbc.M111.223503","article-title":"Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR\/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies","volume":"286","author":"Gaborit","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.critrevonc.2025.104655_bib17","doi-asserted-by":"crossref","first-page":"6375956","DOI":"10.1155\/2020\/6375956","article-title":"Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer","volume":"2020","author":"Gaibar","year":"2020","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104655_bib19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/cas.13314","article-title":"Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer","volume":"108","author":"Gao","year":"2017","journal-title":"Cancer Sci."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104655_bib20","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.hpb.2023.02.016","article-title":"Biliary tract cancers have distinct epidemiological patterns and clinical characteristics according to tumour site","volume":"25","author":"Ghiringhelli","year":"2023","journal-title":"HPB (Oxf. )"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104655_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0149-2918(00)88288-0","article-title":"Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer","volume":"21","author":"Goldenberg","year":"1999","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104655_bib24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"issue":"26","key":"10.1016\/j.critrevonc.2025.104655_bib25","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.3748\/wjg.v22.i26.5879","article-title":"HER2 heterogeneity in gastric\/gastroesophageal cancers: From benchside to practice","volume":"22","author":"Grillo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/289243","article-title":"The roles of mitogen-activated protein kinase pathways in TGF-beta-induced epithelial-mesenchymal transition","volume":"2012","author":"Gui","year":"2012","journal-title":"J. Signal Transduct."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104655_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104655_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/modpathol.2015.57","article-title":"Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)","volume":"28","author":"Hechtman","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104655_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102664","article-title":"HER2 intratumoral heterogeneity in breast cancer, an evolving concept","volume":"15","author":"Hou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"47","key":"10.1016\/j.critrevonc.2025.104655_bib32","doi-asserted-by":"crossref","first-page":"49420","DOI":"10.1074\/jbc.M407700200","article-title":"Critical role of endogenous Akt\/IAPs and MEK1\/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death","volume":"279","author":"Hu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2025.104655_bib33","article-title":"Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency","volume":"83","author":"Huang","year":"2023","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104655_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080290","article-title":"HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study","volume":"8","author":"Huang","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040935","article-title":"Local and central evaluation of HER2 positivity and clinical outcome in advanced gastric and gastroesophageal cancer-results from the AGMT GASTRIC-5 registry","volume":"9","author":"Huemer","year":"2020","journal-title":"J. Clin. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ags3.12691","article-title":"Current progress in perioperative chemotherapy for biliary tract cancer","volume":"7","author":"Ioka","year":"2023","journal-title":"Ann. Gastroenterol. Surg."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104655_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000511919","article-title":"ERBB2 pathway in biliary tract carcinoma: clinical implications of a targetable pathway","volume":"44","author":"Jacobi","year":"2021","journal-title":"Oncol. Res Treat."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104655_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-016-0432-2","article-title":"Genomic profiling of biliary tract cancers and implications for clinical practice","volume":"17","author":"Jain","year":"2016","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13045-015-0155-z","article-title":"HER2\/neu-directed therapy for biliary tract cancer","volume":"8","author":"Javle","year":"2015","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104655_bib41","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100314","article-title":"Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)","volume":"7","author":"Javle","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104655_bib43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104655_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat."},{"issue":"10391","key":"10.1016\/j.critrevonc.2025.104655_bib45","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104655_bib46","first-page":"6971","article-title":"Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma","volume":"61","author":"Kiguchi","year":"2001","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104655_bib47","doi-asserted-by":"crossref","first-page":"e1051","DOI":"10.1093\/oncolo\/oyae076","article-title":"EGFR, HER2, and MET gene amplification and protein expression profiles in biliary tract cancer and their prognostic significance","volume":"29","author":"Kim","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2025.104655_bib48","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Annu Rev. Biochem"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104655_bib49","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1016\/S1470-2045(21)00341-7","article-title":"Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104655_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J. Clin. Med"},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104655_bib51","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1200\/JCO.2012.42.3061","article-title":"Dramatic Response to Trastuzumab and Paclitaxel in a Patient With Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Cholangiocarcinoma","volume":"30","author":"Law","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3233(04)68001-6","article-title":"Structure and function of the epidermal growth factor (EGF\/ErbB) family of receptors","volume":"68","author":"Leahy","year":"2004","journal-title":"Adv. Protein Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib53","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19\u201314)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2468-1253(23)00006-7","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer \u2013 Authors' reply","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"8_ement","key":"10.1016\/j.critrevonc.2025.104655_bib55","article-title":"Abstract CT178: GQ1001: A next generation HER2-targeting ADC that exhibits promising early clinical efficacy with excellent tolerance in a multi-center, Phase Ia study","volume":"83","author":"Lemech","year":"2023","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib56","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/15384047.2016.1139248","article-title":"An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer","volume":"17","author":"Li","year":"2016","journal-title":"Cancer Biol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib57","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.critrevonc.2025.104655_bib58","article-title":"First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed\/refractory solid tumors","volume":"38","author":"Li","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2017.01.021","article-title":"Discovery and development of pyrotinib: A novel irreversible EGFR\/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer","volume":"110","author":"Li","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"15_","key":"10.1016\/j.critrevonc.2025.104655_bib60","article-title":"Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial","volume":"38","author":"Li","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib61","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/CAD.0000000000001558","article-title":"HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report","volume":"35","author":"Liu","year":"2024","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104655_bib62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2011.03.017","article-title":"Antibody-DM1 conjugates as cancer therapeutics","volume":"307","author":"Lopus","year":"2011","journal-title":"Cancer Lett."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104655_bib63","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104655_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143540","article-title":"Trastuzumab mechanism of action; 20 years of research to unravel a Dilemma","volume":"13","author":"Maadi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104655_bib65","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1016\/j.annonc.2023.09.2872","article-title":"148P DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma","volume":"34","author":"Makker","year":"2023","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104655_bib66","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib67","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104655_bib68","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/onco.13800","article-title":"Prolonged response to HER2-directed therapy in three patients with HER2-amplified metastatic carcinoma of the biliary system: case study and review of the literature","volume":"26","author":"May","year":"2021","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104655_bib69","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib71","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00510","article-title":"Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures","author":"Mody","year":"2022","journal-title":"JCO Precis Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104655_bib72","first-page":"4744","article-title":"Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells","volume":"61","author":"Molina","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/PO.19.00223","article-title":"Genomic characterization of ERBB2-driven biliary cancer and a case of response to ado-trastuzumab emtansine","author":"Mondaca","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib74","doi-asserted-by":"crossref","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.09.019","article-title":"18P Trastuzumab in HER2-amplified or overexpressed gallbladder cancer: Experience from an Indian cancer center","volume":"33","author":"Mondal","year":"2022","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104655_bib75","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104655_bib76","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"issue":"16_supp","key":"10.1016\/j.critrevonc.2025.104655_bib77","article-title":"Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): a phase 2 basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104655_bib78","doi-asserted-by":"crossref","first-page":"58007","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104655_bib79","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA Topoisomerase I Inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104655_bib80","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104655_bib81","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104655_bib82","article-title":"Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial","volume":"41","author":"Ohba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112612","article-title":"Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms","volume":"138","author":"Panaampon","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104655_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152756","article-title":"Prognostic significance of EGFR, HER2, and c-met overexpression in surgically treated patients with adenocarcinoma of the ampulla of vater","volume":"16","author":"Park","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000336488","article-title":"HER2\/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib","volume":"82","author":"Peck","year":"2012","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104655_bib86","doi-asserted-by":"crossref","first-page":"366","DOI":"10.33594\/000000144","article-title":"Nuclear ERK translocation is mediated by protein kinase CK2 and accelerated by autophosphorylation","volume":"53","author":"Plotnikov","year":"2019","journal-title":"Cell Physiol. Biochem"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104655_bib87","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib88","doi-asserted-by":"crossref","first-page":"403","DOI":"10.14701\/ahbps.2019.23.4.403","article-title":"Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection","volume":"23","author":"Prieto","year":"2019","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104655_bib89","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib90","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-009-0927-7","article-title":"A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer","volume":"64","author":"Ramanathan","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib91","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.S3","article-title":"The basic biology of HER2","volume":"12","author":"Rubin","year":"2001","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104655_bib92","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","article-title":"Growing roles for the mTOR pathway","volume":"17","author":"Sarbassov","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.104655_bib93","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib94","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040684","article-title":"Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States","volume":"16","author":"Storandt","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104655_bib96","article-title":"Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies","volume":"37","author":"Tan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4_","key":"10.1016\/j.critrevonc.2025.104655_bib97","article-title":"A glimpse into the future of cholangiocarcinoma: Predicting the future incidence based on the current epidemiological data","volume":"41","author":"Tella","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102806","article-title":"Antibody-drug conjugates for hepato-pancreato-biliary malignancies: \u201cMagic bullets\u201d to the rescue?","volume":"129","author":"Theocharopoulos","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104655_bib99","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920962997","article-title":"An overview of antibody-drug conjugates in oncological practice","volume":"12","author":"Theocharopoulos","year":"2020","journal-title":"Ther. Adv. Med Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104655_bib100","article-title":"Antibody-drug conjugates: functional principles and applications in oncology and beyond","volume":"9","author":"Theocharopoulos","year":"2021","journal-title":"Vaccin. (Basel)"},{"issue":"32","key":"10.1016\/j.critrevonc.2025.104655_bib101","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.3748\/wjg.v16.i32.4047","article-title":"High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT\/p70S6K","volume":"16","author":"Treekitkarnmongkol","year":"2010","journal-title":"World J. Gastroenterol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104655_bib102","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104655_bib103","doi-asserted-by":"crossref","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","article-title":"Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2","volume":"67","author":"Varchetta","year":"2007","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104655_bib104","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO scale for clinical actionability of molecular targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104655_bib105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104655_bib106","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104655_bib107","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104655_bib108","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"de Vries","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2025.104655_bib109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102415","article-title":"Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial","volume":"68","author":"Wang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.critrevonc.2025.104655_bib111","first-page":"4233782","article-title":"Retrospective study on the efficacy and safety of pyrotinib-based therapy for HER2-positive nonbreast advanced solid tumors","volume":"2022","author":"Wang","year":"2022","journal-title":"J. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib112","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib113","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104655_bib114","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-019-03768-8","article-title":"Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate","volume":"83","author":"Yamashita-Kashima","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib115","doi-asserted-by":"crossref","first-page":"S461","DOI":"10.1016\/j.annonc.2023.09.1842","article-title":"656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing\/mutated advanced non-breast solid tumors (STs): results from the global phase I study","volume":"34","author":"Yao","year":"2023","journal-title":"Ann. Oncol."},{"issue":"12_ement","key":"10.1016\/j.critrevonc.2025.104655_bib116","article-title":"Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations","volume":"82","author":"Yap","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41698-019-0091-4","article-title":"Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma","volume":"3","author":"Yarlagadda","year":"2019","journal-title":"npj Precis. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104655_bib118","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"Yoo","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104655_bib119","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1016\/j.annonc.2022.07.083","article-title":"55P Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)\/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)","volume":"33","author":"Yoo","year":"2022","journal-title":"Ann. Oncol."},{"issue":"8_ement","key":"10.1016\/j.critrevonc.2025.104655_bib120","article-title":"Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104655_bib121","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12957-023-02983-1","article-title":"Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report","volume":"21","author":"Zhang","year":"2023","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104655_bib122","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/hep.23773","article-title":"Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy","volume":"52","author":"Zhang","year":"2010","journal-title":"Hepatology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:03:44Z","timestamp":1741608224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":122,"alternative-id":["S1040842825000435"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104655","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2-targeted therapies: Unraveling their role in biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104655"}}